Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

BACKGROUND: This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment-experienced patients. METHODS: Patients who had...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Infect Dis
Main Authors: Gane, Edward J., DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457573/
https://ncbi.nlm.nih.gov/pubmed/28577353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-017-2444-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares